bluebird bio Inc. (Nasdaq: BLUE) reported positive updated data from an ongoing HGB-205 clinical study of LentiGlobin to treat severe sickle cell disease and transfusion-dependent B-thalassemia. Shares of the biotechnology firm leaped $30.65 to close at $201.80.
bluebird bio reports upbeat data
December 11, 2017 at 17:15 PM EST
